Urology resident at @VUMCUrology by way of @Iowamed. RT, like, follow does not = endorsement.
Nashville, TN
Joined September 2021
- Tweets52
- Following141
- Followers96
- Likes449
Ian McElree retweeted
New in @EurUrolFocus: Extended Outcomes of Intravesical Valrubicin and Docetaxel as a Secondary Salvage Treatment for Recalcitrant High-risk Non-muscle-invasive Bladder Cancer. buff.ly/FpMRQX8
#MikeODonnell @HougenHY @ryansteinbergmd
Ian McElree retweeted
More great work by @IanMcelree on the importance of bluelight & checking sanctuary sites in post induction HR NMIBC. Esp ๐ when considering multiple rounds of salvage therapy!
@HougenHY @VigneshPackiam #MikeODonnell @UIowa_urology
journals.sagepub.com/doi/10.โฆ
Ian McElree retweeted
New in @EurUrolOncol, including @UIowa_urology authors Dr. Michael A. O'Donnell, Dr. Jordan R. Richards, and @IanMcelree: Investigation of first AI-powered histologic biomarker for patients with untreated high-grade NMIBC: buff.ly/bijSZKE
Ian McElree retweeted
We are thrilled to share our recent publication in @EurUrolOncol demonstrating for the first time CHAI based predictive biomarker to guide use of intravesical BCG vs alternatives (chemotherapy). In an era of BCG shortage and new alternatives to BCG incoming, precision medicine based tools to guide intravesical treatment choice will enable improved patient care in bladder cancer.
Incredible collaborative effort with bladder cancer experts @VigneshPackiam @pjhensley11 @UroDocAsh @saumyg @SWilliams_MD @IanMcelree @YairLotan
euoncology.europeanurology.cโฆ
Ian McElree retweeted
Fantastic work by super โญ๏ธ @IanMcelree presenting @UIowa_urology data on restaging procedures for NMIBC. An important step when considering multiple salvage intravesical therapies. Keep an eye out for him in this yearโs match! #NCSAUA24
@NCSAUA @VigneshPackiam
Ian McElree retweeted
Another intravesicular regimen (cabazitaxel+ Gem) by Mike O'Donnell @UIowaCancer with pembro, in refractory HRNMIBC (Doce failure), interesting results, prospective study underway. Honored to be part of this effort.
mdpi.com/2873358 #mdpicancers via @Cancers_MDPI
Ian McElree retweeted
Nice paper @ReubenBenDavid1 @DrJohnSfakianos !! Important to learn optimal Gem/Doce protocol. Data like this on the implications of maintenance are valuable. Anecdotally I have found that 2g Gem in combo regimens has more tol issues @saumyg @RutgersCancer @rwjurology @IanMcelree
Excited about our latest publication!
Gem/Doce induction + maintenance is superior to induction only. The use of 2 grams of gemcitabine improved all grades of recurrence but didn't decrease high-grade recurrences over 1 gram of gemcitabine.
Gem/Doce is gaining grounds in the treatment of NMIBC.
@DrJohnSfakianos @MehrazinMD @NDTillu
link.springer.com/article/10โฆ
Ian McElree retweeted
Fantastic work by @IanMcelree (as always!) presenting on BCG vs Gem/Doce in upper tract CIS. Similar outcomes with regards to RFS/NFS/OS. But be careful of the potential for infection!
#AUA24 #SaveTheNephrons #GemDoce #UTUC
@VigneshPackiam @UIowa_urology
Ian McElree retweeted
Ecstatic and humbled to be joining @MayoUrology for residency! What a dream come true. Rochester, here we come! ๐๐๐
#auamatch #uromatch #urosome #IowaMatch2024
Ian McElree retweeted
Such a privilege to continue working with @IanMcelree on use of endoluminal Gem/Doce, now for #UTUC
Takeaways:
๐ก 41 upper tracts - 90% CIS (most had + cytology)
๐ก 2 yr-RFS 54%, 2yr-NephUFS 92%
๐ก ๐ค selection is ๐
#GemDoce #SaveTheNephrons โจ
@VigneshPackiam @UIowa_urology
Sequential endoluminal gemcitabine and docetaxel for the treatment of clinically non-invasive high-grade upper tract urothelial carcinoma buff.ly/3tBDvsZ
Ian McElree retweeted
๐ฅNew ๐ Alert๐ฅ
Gem/Doce for HG Favorable UTUC
๐41 UT units, 90% CIS (+cytology)
๐2yr RFS 54%, 3yr PFS 75%
๐2 yr NephU Free 92%
๐ 5 pts died of UTUC
Reasonable option 4 selected patients!
tinyurl.com/GemDoceUTUC
@UIowa_urology @VigneshPackiam @IanMcelree #MikeODonnell
Ian McElree retweeted
Continued great work by super ๐ @IanMcelree
Gem/Doce effective in treatment naive (79% 2 year RFS) and previously treated (64%) Intermediate Risk NMIBC
@ryansteinbergmd @JOrzel_MD @BladderCancerUS @SUO_YUO
Can be considered for various disease states
pubmed.ncbi.nlm.nih.gov/3744โฆ
Ian McElree retweeted
Pooling together patients from @MDAndersonNews @MoffittNews @uiowa we report outcomes of IR-NMIBC patients treated with Gem-Doce vs BCG in @EurUrolOncol
@IanMcelree @FDavaro @ryansteinbergmd @KKBree @nnavai #ColinDinney #MikeODonnell @UrogerliMD @UroDocAsh @VigneshPackiam
Ian McElree retweeted
Really impactful science @LauraBukavinaMD - you are awesome work with!
Gem/Doce ๐๐๐ this is great for our patients
Important translational work in the works @IanMcelree @MaxKates @eugene_pietzak @saumyg @BladderCancerUS โ at Iowa City, IA
Someday soon enough bcg is not going to be the standard of care #nmibc โฆ alternative therapies are coming . In the meantime Iโll keep sending my napkin results to @VigneshPackiam and our ๐ results .. 40% CR Gem Doce / 40 % CR alternative ๐ฆ .. bcg ๐๐ป #bladdercancer
Ian McElree retweeted
Someday soon enough bcg is not going to be the standard of care #nmibc โฆ alternative therapies are coming . In the meantime Iโll keep sending my napkin results to @VigneshPackiam and our ๐ results .. 40% CR Gem Doce / 40 % CR alternative ๐ฆ .. bcg ๐๐ป #bladdercancer
What an honor - Thanks @JUrology for recognizing our work ๐ซก Still much to be done! @VigneshPackiam @ryansteinbergmd
Change is good!
As usual a killer presentation by @IanMcelree about Gem/Doce for intermediate risk NMIBC @DrMBWesterman @gershmanMD @UIowa_urology #AUA23
79% 2 year complete response in treatment naive
Ian McElree retweeted
Further evidence that Gem/Doce is reasonable alternative to BCG in patients with high-risk NMIBC, during the ongoing BCG shortage @IanMcelree @VigneshPackiam @ryansteinbergmd @uiowa
ja.ma/41ToYFt @JAMANetworkOpen @JAMANetwork
#Bridge Trial @MaxKates @angiesmith_uro
Ian McElree retweeted
Gem+Doce is associated with better 2yr high-grade recurrence-free survival (81% vs 69%), less treatment discontinuation (3% vs 9%) vs BCG in patients with nonโmuscle-invasive bladder cancer; may be useful during BCG shortage. @VigneshPackiam @IanMcElree ja.ma/3IGhX1U
Ian McElree retweeted
Just out in @JAMANetworkOpen ๐จ
@UIowa_urology @VigneshPackiam show Gem/doce associated w/ nearly 50% reduction in recurrences and lower rate of tx discontinuation compared to bcg for high risk #nmibc ๐
@UroOnc @BladderCancerUS @urotoday
Link: tinyurl.com/m6yf3nc3
